Search

Your search keyword '"Morabito A"' showing total 156 results
Start Over Author "Morabito A" Journal journal of thoracic oncology
156 results on '"Morabito A"'

1. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)

Author

Ou, Sai-Hong Ignatius, Nishio, Makoto, Ahn, Myung-Ju, Mok, Tony, Barlesi, Fabrice, Zhou, Caicun, Felip, Enriqueta, de Marinis, Filippo, Kim, Sang-We, Pérol, Maurice, Liu, Geoffrey, Migliorino, Maria Rita, Kim, Dong-Wan, Novello, Silvia, Bearz, Alessandra, Garrido, Pilar, Mazieres, Julien, Morabito, Alessandro, Lin, Huamao M., Yang, Hui, Niu, Huifeng, Zhang, Pingkuan, and Kim, Edward S.

Published
2022
Full Text
View/download PDF

3. Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)

Author

Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, Wei Tu, Courtney H. Coschi, Federica Grosso, Marie Florescu, Manlio Mencoboni, John R. Goffin, Maria Pagano, Fortunato Ciardiello, Fabiana Letizia Cecere, Mark Vincent, Roberto Ferrara, David E. Dawe, Desiree Hao, Christopher W. Lee, Alessandro Morabito, Cesare Gridelli, Luigi Cavanna, Mussawar Iqbal, Normand Blais, Natasha B. Leighl, Paul Wheatley-Price, Ming-Sound Tsao, Francesca Ugo, Hazem El-Osta, Piera Gargiulo, Pierre-Olivier Gaudreau, Dongsheng Tu, Joana Sederias, Pamela Brown-Walker, Francesco Perrone, Lesley Seymour, and Scott A. Laurie

Subjects
Pulmonary and Respiratory Medicine, Oncology
Published
2023

4. EP17.06-01 COVID-19 Long-Lasting Effect on Lung Cancer Diagnoses in Italy: Update of the Real-World Multicenter COVID-DELAY Study

Author

Mentrasti, G., primary, Cognigni, V., additional, Galassi, T., additional, Signorelli, D., additional, Pizzutilo, E.G., additional, Martinelli, F., additional, Lo Russo, G., additional, Leporati, R., additional, Ambrosini, P., additional, Giusti, R., additional, D'Amuri, S., additional, Rocco, D., additional, Della Gravara, L., additional, Antonuzzo, L., additional, Fancelli, S., additional, Gori, S., additional, Sernia, S., additional, Ferrari, M., additional, De Tursi, M., additional, Di Marino, P., additional, Di Maio, M., additional, Salerno, F., additional, Zumstein, L., additional, Russano, M., additional, Citarella, F., additional, Adamo, V., additional, Russo, A., additional, Scimone, C., additional, Sforza, V., additional, Morabito, A., additional, La Verde, N., additional, Cona, M.S., additional, Catalano, V., additional, Emili, R., additional, Sarti, D., additional, Morgillo, F., additional, Di Guida, G., additional, Rocchi, M.B.L., additional, Parisi, A., additional, and Berardi, R., additional

Published
2023
Full Text
View/download PDF

5. Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial

Author

Maria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino, Giovanna Esposito, Claudio Dazzi, Luigi Cavanna, Marco Angelo Burgio, Francesco Rosetti, Simona Rizzato, Floriana Morgillo, Saverio Cinieri, Antonello Veccia, Maximilan Papi, Giuseppe Tonini, Vittorio Gebbia, Serena Ricciardi, Daniele Pozzessere, Alessandra Ferro, Claudia Proto, Raffaele Costanzo, Manolo D’Arcangelo, Manuela Proietto, Piera Gargiulo, Raimondo Di Liello, Laura Arenare, Filippo De Marinis, Lucio Crinò, Fortunato Ciardiello, Nicola Normanno, Ciro Gallo, Francesco Perrone, Cesare Gridelli, Alessandro Morabito, Piccirillo, Maria Carmela, Bonanno, Laura, Garassino, Marina Chiara, Esposito, Giovanna, Dazzi, Claudio, Cavanna, Luigi, Burgio, Marco Angelo, Rosetti, Francesco, Rizzato, Simona, Morgillo, Floriana, Cinieri, Saverio, Veccia, Antonello, Papi, Maximilan, Tonini, Giuseppe, Gebbia, Vittorio, Ricciardi, Serena, Pozzessere, Daniele, Ferro, Alessandra, Proto, Claudia, Costanzo, Raffaele, D'Arcangelo, Manolo, Proietto, Manuela, Gargiulo, Piera, Di Liello, Raimondo, Arenare, Laura, De Marinis, Filippo, Crinò, Lucio, Ciardiello, Fortunato, Normanno, Nicola, Gallo, Ciro, Perrone, Francesco, Gridelli, Cesare, and Morabito, Alessandro

Subjects
Pulmonary and Respiratory Medicine, Lung Neoplasms, EGFR, NSCLC, Bevacizumab, ErbB Receptors, Erlotinib Hydrochloride, Oncology, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Mutation, Humans, Randomized clinical trial, Protein Kinase Inhibitors
Abstract

Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited data were available in non-Asian patients. BEVERLY is an Italian, multicenter, randomized, phase 3 investigating the addition of bevacizumab to erlotinib as first-line treatment of advanced EGFR-mutated NSCLC.Eligible patients were randomized 1:1 to erlotinib plus bevacizumab or erlotinib alone. Investigator-assessed PFS and blinded independent centrally reviewed PFS were coprimary end points. With 80% power in detecting a 0.60 hazard ratio and two-sided α error of 0.05, 126 events of 160 patients were needed. The trial was registered as NCT02633189 and EudraCT 2015-002235-17.From April 11, 2016, to February 27, 2019, a total of 160 patients were randomized to erlotinib plus bevacizumab (80) or erlotinib alone (80). At a median follow-up of 36.3 months, median investigator-assessed PFS was 15.4 months (95% confidence interval [CI]: 12.2-18.6) with erlotinib plus bevacizumab and 9.6 months (95% CI: 8.2-10.6) with erlotinib alone (hazard ratio = 0.66, 95% CI: 0.47-0.92). Blinded independent centrally reviewed PFS analysis confirmed this result. A statistically significant interaction with treatment effect was found for smoking habit (p = 0.0323), with PFS prolongation being clinically significant only among current or previous smokers. Hypertension (grade ≥3: 24% versus 5%), skin rash (grade ≥ 3: 31% versus 14%), thromboembolic events (any grade: 11% versus 4%), and proteinuria (any grade: 23% versus 6%) were more frequent with the combination.The addition of bevacizumab to first-line erlotinib prolonged PFS in Italian patients with EGFR-mutated NSCLC; toxicity was increased with the combination but without unexpected safety issues.

Published
2022

6. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)

Author

Sai-Hong Ignatius, Ou, Makoto, Nishio, Myung-Ju, Ahn, Tony, Mok, Fabrice, Barlesi, Caicun, Zhou, Enriqueta, Felip, Filippo, de Marinis, Sang-We, Kim, Maurice, Pérol, Geoffrey, Liu, Maria Rita, Migliorino, Dong-Wan, Kim, Silvia, Novello, Alessandra, Bearz, Pilar, Garrido, Julien, Mazieres, Alessandro, Morabito, Huamao M, Lin, Hui, Yang, Huifeng, Niu, Pingkuan, Zhang, Edward S, Kim, Institut Català de la Salut, [Ou SI] Department of Medicine, Division of Hematology-Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California. [Nishio M] Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. [Ahn MJ] Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. [Mok T] State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, People’s Republic of China. [Barlesi F] Aix-Marseille University, CNRS, INSERM, CRCM, Marseille, France. Multidisciplinary Oncology & Therapeutic Innovations Department, Gustave Roussy Cancer Campus, Villejuif, France. [Zhou C] Shanghai Pulmonary Hospital, Shanghai, People’s Republic of China. [Felip E] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Pulmonary and Respiratory Medicine, Lung Neoplasms, Otros calificadores::/uso terapéutico [Otros calificadores], Carbazoles, Medicaments antineoplàstics - Ús terapèutic, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS], diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung [DISEASES], neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas [ENFERMEDADES], Other subheadings::Other subheadings::/drug therapy [Other subheadings], Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Oncology, Carcinoma, Non-Small-Cell Lung, Avaluació de resultats (Assistència sanitària), Humans, Anaplastic Lymphoma Kinase, Other subheadings::/therapeutic use [Other subheadings], Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS], Pulmons - Càncer - Tractament, Protein Kinase Inhibitors
Abstract

Circulating tumor DNA; Non–small cell lung cancer; Tumor biomarker ADN tumoral circulante; Cáncer de pulmón de células no pequeñas; Biomarcador tumoral ADN tumoral circulant; Càncer de pulmó de cèl·lules no petites; Biomarcador tumoral Introduction Brigatinib is a potent next-generation ALK tyrosine kinase inhibitor approved for treatment-naive and crizotinib-refractory advanced ALK-positive (ALK+) NSCLC. We evaluated brigatinib after other next-generation ALK tyrosine kinase inhibitors. Methods In this single-arm, phase 2, ALK in Lung Cancer Trial of brigAtinib-2 (NCT03535740), patients with advanced ALK+ NSCLC whose disease progressed on alectinib or ceritinib received brigatinib 180 mg once daily (after 7-d 90-mg lead-in). Primary end point was independent review committee (IRC)-assessed overall response rate (ORR). Circulating tumor DNA (ctDNA) was analyzed. Results Among 103 patients (data cutoff: September 30, 2020; median follow-up [range]: 10.8 [0.5–17.7] mo), confirmed IRC-ORR was 26.2% (95% confidence interval [CI]: 18.0–35.8), median duration of response, 6.3 months (95% CI: 5.6–not reached), and median progression-free survival (mPFS), 3.8 months (95% CI: 3.5–5.8). mPFS was 1.9 months (95% CI: 1.8–3.7) in patients with ctDNA-detectable baseline ALK fusion (n = 64). Among 86 patients who progressed on alectinib, IRC-ORR was 29.1% (95% CI: 19.8–39.9); mPFS was 3.8 months (95% CI: 1.9–5.4). Resistance mutations were present in 33.3% (26 of 78) of baseline ctDNA; 54% (14 of 26) of mutations were G1202R; 52% (33 of 64) of patients with detectable ALK fusion had EML4-ALK variant 3. Most common all-grade treatment-related adverse events were increased creatine phosphokinase (32%) and diarrhea (27%). The mean dose intensity of brigatinib (180 mg once daily) was 85.9%. Conclusions In ALK in Lung Cancer Trial of brigAtinib-2, brigatinib was found to have a limited activity in patients with ALK+ NSCLC post-ceritinib or post-alectinib therapy. mPFS was longer with brigatinib in patients without baseline detectable plasma ALK fusion.

Published
2022

7. Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171).

Author

Piccirillo, Maria Carmela, primary, Chu, Quincy, additional, Bradbury, Penelope, additional, Tu, Wei, additional, Coschi, Courtney H., additional, Grosso, Federica, additional, Florescu, Marie, additional, Mencoboni, Manlio, additional, Goffin, John R., additional, Pagano, Maria, additional, Ciardiello, Fortunato, additional, Cecere, Fabiana Letizia, additional, Vincent, Mark, additional, Ferrara, Roberto, additional, Dawe, David E., additional, Hao, Desiree, additional, Lee, Christopher W., additional, Morabito, Alessandro, additional, Gridelli, Cesare, additional, Cavanna, Luigi, additional, Iqbal, Mussawar, additional, Blais, Normand, additional, Leighl, Natasha B., additional, Wheatley-Price, Paul, additional, Tsao, Ming-Sound, additional, Ugo, Francesca, additional, El-Osta, Hazem, additional, Gargiulo, Piera, additional, Gaudreau, Pierre-Olivier, additional, Tu, Dongsheng, additional, Sederias, Joana, additional, Brown-Walker, Pamela, additional, Perrone, Francesco, additional, Seymour, Lesley, additional, and Laurie, Scott A., additional

Published
2023
Full Text
View/download PDF

8. Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)

Author

Piccirillo, Maria Carmela, Chu, Quincy, Bradbury, Penelope, Tu, Wei, Coschi, Courtney H., Grosso, Federica, Florescu, Marie, Mencoboni, Manlio, Goffin, John R., Pagano, Maria, Ciardiello, Fortunato, Cecere, Fabiana Letizia, Vincent, Mark, Ferrara, Roberto, Dawe, David E., Hao, Desiree, Lee, Christopher W., Morabito, Alessandro, Gridelli, Cesare, Cavanna, Luigi, Iqbal, Mussawar, Blais, Normand, Leighl, Natasha B., Wheatley-Price, Paul, Tsao, Ming-Sound, Ugo, Francesca, El-Osta, Hazem, Gargiulo, Piera, Gaudreau, Pierre-Olivier, Tu, Dongsheng, Sederias, Joana, Brown-Walker, Pamela, Perrone, Francesco, Seymour, Lesley, and Laurie, Scott A.

Published
2023
Full Text
View/download PDF

9. Erratum to "Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813–819]".

Author

Piccirillo, Maria Carmela, Chu, Quincy, Bradbury, Penelope, Tu, Wei, Coschi, Courtney H., Grosso, Federica, Florescu, Marie, Mencoboni, Manlio, Goffin, John R., Pagano, Maria, Ciardiello, Fortunato, Cecere, Fabiana Letizia, Vincent, Mark, Ferrara, Roberto, Dawe, David E., Hao, Desiree, Lee, Christopher W., Morabito, Alessandro, Gridelli, Cesare, and Cavanna, Luigi

Published
2024
Full Text
View/download PDF

11. Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial

Author

Piccirillo, Maria Carmela, primary, Bonanno, Laura, additional, Garassino, Marina Chiara, additional, Esposito, Giovanna, additional, Dazzi, Claudio, additional, Cavanna, Luigi, additional, Burgio, Marco Angelo, additional, Rosetti, Francesco, additional, Rizzato, Simona, additional, Morgillo, Floriana, additional, Cinieri, Saverio, additional, Veccia, Antonello, additional, Papi, Maximilan, additional, Tonini, Giuseppe, additional, Gebbia, Vittorio, additional, Ricciardi, Serena, additional, Pozzessere, Daniele, additional, Ferro, Alessandra, additional, Proto, Claudia, additional, Costanzo, Raffaele, additional, D’Arcangelo, Manolo, additional, Proietto, Manuela, additional, Gargiulo, Piera, additional, Di Liello, Raimondo, additional, Arenare, Laura, additional, De Marinis, Filippo, additional, Crinò, Lucio, additional, Ciardiello, Fortunato, additional, Normanno, Nicola, additional, Gallo, Ciro, additional, Perrone, Francesco, additional, Gridelli, Cesare, additional, and Morabito, Alessandro, additional

Published
2022
Full Text
View/download PDF

12. EP06.01-006 Multidisciplinary Team during the COVID-19 Pandemic: The BE-PACIFIC Italian Observational Study Analysis

Author

Ramella, S., primary, Morabito, A., additional, Silipigni, S., additional, Russo, A., additional, Capelletto, E., additional, Rossi, S., additional, Leonetti, A., additional, Montrone, M., additional, Facilissimo, I., additional, Romano, G., additional, Stasi, I., additional, Ceresoli, G., additional, Gridelli, C., additional, Lugini, A., additional, Pilotto, S., additional, Tagliaferri, P., additional, Bria, E., additional, Canova, S., additional, Rijavec, E., additional, Borghetti, P., additional, Brighenti, M., additional, Carta, A.M., additional, Ciuffreda, L., additional, Giusti, R., additional, Macerelli, M., additional, Verderame, F., additional, Zanelli, F., additional, Berardi, R., additional, Gregorc, V., additional, Sergi, C., additional, Vattemi, E., additional, Manglaviti, S., additional, Piovano, P.L., additional, Olmetto, E., additional, Borra, G., additional, Gori, S., additional, Aieta, M., additional, Bertolini, A., additional, Cecere, F., additional, Pasello, G., additional, Rocco, D., additional, Zulian, M., additional, Roncari, B., additional, and Novello, S., additional

Published
2022
Full Text
View/download PDF

13. EP05.01-024 Real-life Management of Stage III NSCLC Patients in Italy: The BE-PACIFIC Observational Study

Author

Novello, S., primary, Morabito, A., additional, Silipigni, S., additional, Adamo, V., additional, Bironzo, P., additional, Rossi, S., additional, Tiseo, M., additional, Montrone, M., additional, Facilissimo, I., additional, Romano, G., additional, Stasi, I., additional, Ceresoli, G., additional, Gridelli, C., additional, Lugini, A., additional, Pilotto, S., additional, Tagliaferri, P., additional, Bria, E., additional, Cortinovis, D., additional, Grossi, F., additional, Borghetti, P., additional, Brighenti, M., additional, Carta, A.M., additional, Ciuffreda, L., additional, Giusti, R., additional, Macerelli, M., additional, Verderame, F., additional, Zanelli, F., additional, Berardi, R., additional, Gregorc, V., additional, Sergi, C., additional, Vattemi, E., additional, Ferrara, R., additional, Piovano, P.L., additional, Scotti, V., additional, Borra, G., additional, Gori, S., additional, Aieta, M., additional, Bertolini, A., additional, Cecere, F., additional, Pasello, G., additional, Rocco, D., additional, Lo Certo, G., additional, Simoni, L., additional, and Ramella, S., additional

Published
2022
Full Text
View/download PDF

14. EP08.02-048 Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial

Author

Cappuzzo, F., primary, Chiari, R., additional, Tiseo, M., additional, Minotti, V., additional, De Marinis, F., additional, Delmonte, A., additional, Bungaro, M., additional, Cortinovis, D.L., additional, Galetta, D., additional, Bonanno, L., additional, Chella, A., additional, Gridelli, C., additional, Morabito, A., additional, Grossi, F., additional, Bria, E., additional, Giannarelli, D., additional, Fontanini, G., additional, Borra, G., additional, Gori, S., additional, Mazzoni, F., additional, Pilotto, S., additional, and Landi, L., additional

Published
2022
Full Text
View/download PDF

15. EP05.01-024 Real-life Management of Stage III NSCLC Patients in Italy: The BE-PACIFIC Observational Study

Author

S. Novello, A. Morabito, S. Silipigni, V. Adamo, P. Bironzo, S. Rossi, M. Tiseo, M. Montrone, I. Facilissimo, G. Romano, I. Stasi, G. Ceresoli, C. Gridelli, A. Lugini, S. Pilotto, P. Tagliaferri, E. Bria, D. Cortinovis, F. Grossi, P. Borghetti, M. Brighenti, A.M. Carta, L. Ciuffreda, R. Giusti, M. Macerelli, F. Verderame, F. Zanelli, R. Berardi, V. Gregorc, C. Sergi, E. Vattemi, R. Ferrara, P.L. Piovano, V. Scotti, G. Borra, S. Gori, M. Aieta, A. Bertolini, F. Cecere, G. Pasello, D. Rocco, G. Lo Certo, L. Simoni, and S. Ramella

Subjects
Pulmonary and Respiratory Medicine, Oncology
Published
2022

16. EP06.01-006 Multidisciplinary Team during the COVID-19 Pandemic: The BE-PACIFIC Italian Observational Study Analysis

Author

S. Ramella, A. Morabito, S. Silipigni, A. Russo, E. Capelletto, S. Rossi, A. Leonetti, M. Montrone, I. Facilissimo, G. Romano, I. Stasi, G. Ceresoli, C. Gridelli, A. Lugini, S. Pilotto, P. Tagliaferri, E. Bria, S. Canova, E. Rijavec, P. Borghetti, M. Brighenti, A.M. Carta, L. Ciuffreda, R. Giusti, M. Macerelli, F. Verderame, F. Zanelli, R. Berardi, V. Gregorc, C. Sergi, E. Vattemi, S. Manglaviti, P.L. Piovano, E. Olmetto, G. Borra, S. Gori, M. Aieta, A. Bertolini, F. Cecere, G. Pasello, D. Rocco, M. Zulian, B. Roncari, and S. Novello

Subjects
Pulmonary and Respiratory Medicine, Oncology
Published
2022

18. OA01.02 Impact of COVID-19 Outbreak on Lung Cancer Diagnosis and Continuum of Care: Data From an Italian Multicenter Study

Author

Cantini, L., primary, Mentrasti, G., additional, Siena, S., additional, Pasello, G., additional, Galetti, A., additional, Caliman, E., additional, Rocco, D., additional, Adamo, V., additional, Genova, C., additional, Morabito, A., additional, Gori, S., additional, Rijavec, E., additional, Chiari, R., additional, Oldani, S., additional, Caglio, A., additional, De Tursi, M., additional, Cortellini, A., additional, Morgillo, F., additional, Bennati, C., additional, Guida, A., additional, Spinelli, G.P., additional, Emili, R., additional, Roca, E., additional, Indini, A., additional, De Toma, A., additional, Vallini, I., additional, D'Emilio, V., additional, Cognigni, V., additional, Pecci, F., additional, Migliore, A., additional, Della Gravara, L., additional, Frega, S., additional, Zullo, L., additional, Zattarin, E., additional, Citarella, F., additional, Russo, A., additional, Fancelli, S., additional, Oresti, S., additional, and Berardi, R., additional

Published
2021
Full Text
View/download PDF

19. Lungs on Fire

Author

Rocco, Gaetano, Morabito, Alessandro, Petrillo, Antonella, and Catalano, Orlando

Published
2015
Full Text
View/download PDF

20. OA01.02 Impact of COVID-19 Outbreak on Lung Cancer Diagnosis and Continuum of Care: Data From an Italian Multicenter Study

Author

Chiara Bennati, S. Oldani, Lodovica Zullo, R. Emili, Elisa Roca, Valeria Cognigni, Vincenzo Adamo, A. Migliore, Luca Cantini, Salvatore Siena, E. Caliman, Ilaria Vallini, Stefano Frega, Rita Chiari, V. D'Emilio, Giulia Pasello, Alice Indini, Alessio Cortellini, L. Della Gravara, R. Berardi, Gian Paolo Spinelli, A. Galetti, S. Fancelli, S. Oresti, E. Rijavec, Carlo Genova, Danilo Rocco, A. De Toma, Alessandro Morabito, Fabrizio Citarella, A. Guida, M. De Tursi, Antonio Russo, Andrea Caglio, Emma Zattarin, Stefania Gori, Federica Pecci, Giulia Mentrasti, and Floriana Morgillo

Subjects
Pulmonary and Respiratory Medicine, 2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Oa01 the Impact of Covid-19 on Patients with Lung Cancer Wednesday, September 08, 2021 - 08:15-09:15, Outbreak, medicine.disease, Oncology, Multicenter study, Emergency medicine, medicine, Continuum of care, Lung cancer, business
Published
2021

21. 167P Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small cell lung cancer (aNSCLC): A pooled analysis of 6 randomized trials

Author

Gargiulo, P., primary, Di Liello, R., additional, Arenare, L., additional, Gridelli, C., additional, Morabito, A., additional, Ciardiello, F., additional, Gebbia, V., additional, Maione, P., additional, Spagnuolo, A., additional, Palumbo, G., additional, Esposito, G., additional, Della Corte, C.M., additional, Morgillo, F., additional, Mancuso, G., additional, Gravina, A., additional, Schettino, C., additional, Di Maio, M., additional, Gallo, C., additional, Perrone, F., additional, and Piccirillo, M.C., additional

Published
2021
Full Text
View/download PDF

22. P30.02 Assessing SIADH (Syndrome of Inapproriate Antidiuretic Hormone Secretion) Management and Outcome Among Lung Cancer Patients: The Assert Trial

Author

Berardi, R., primary, Garassino, M.C., additional, Tiseo, M., additional, Palazzo, S., additional, Montesarchio, V., additional, Tonini, G., additional, Cavanna, L., additional, Ferrari, D., additional, Palermo, L., additional, Rijavec, E., additional, Altavilla, G., additional, Morabito, A., additional, Pinotti, G., additional, Buosi, R., additional, Cognetti, F., additional, Scartozzi, M., additional, Gori, S., additional, Torniai, M., additional, and De Marino, V., additional

Published
2021
Full Text
View/download PDF

23. PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results

Author

Novello, S., primary, Monica, V., additional, Serke, M., additional, Grohe, C., additional, Meyer, A., additional, Geissler, M., additional, Colantonio, I., additional, Stoelben, E., additional, Cecere, F., additional, Schutte, W., additional, Schumann, C., additional, Valmadre, G., additional, Borra, G., additional, Schena, M., additional, Morabito, A., additional, Santo, A., additional, Chiari, R., additional, Gregorc, V., additional, Reck, M., additional, Manegold, C., additional, Griesinger, F., additional, Follador, A., additional, Ferrari, A., additional, Bearz, A., additional, Caffo, O., additional, Dickgreber, N., additional, Irtelli, L., additional, Wiest, G.h., additional, Sotoparra, H., additional, Spatafora, M., additional, Righi, L., additional, Torri, V., additional, Porcu, L., additional, Arizio, F., additional, and Scagliotti, G., additional

Published
2021
Full Text
View/download PDF

24. 167P Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small cell lung cancer (aNSCLC): A pooled analysis of 6 randomized trials

Author

R. Di Liello, Ciro Gallo, Alessia Spagnuolo, M. Di Maio, Mauro Piccirillo, Francesco Perrone, C. Gridelli, C.M. Della Corte, Fortunato Ciardiello, Adriano Gravina, Clorinda Schettino, Vittorio Gebbia, Alessandro Morabito, Piera Gargiulo, Gianfranco Mancuso, Floriana Morgillo, P. Maione, Laura Arenare, Grazia Esposito, and Giuliano Palumbo

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Neutropenia, medicine.disease, Treatment efficacy, law.invention, Pooled analysis, Randomized controlled trial, Chemotherapy induced, law, Internal medicine, medicine, Non small cell, Lung cancer, business
Published
2021

25. P30.02 Assessing SIADH (Syndrome of Inapproriate Antidiuretic Hormone Secretion) Management and Outcome Among Lung Cancer Patients: The Assert Trial

Author

M.C. Garassino, Erika Rijavec, Stefania Gori, R. Berardi, M. Scartozzi, V. De Marino, V. Montesarchio, Giuseppe Altavilla, G. Tonini, Luigi Cavanna, L. Palermo, Roberta Buosi, Daris Ferrari, Francesco Cognetti, M. Tiseo, Mariangela Torniai, Graziella Pinotti, Alberto Morabito, and Salvatore Palazzo

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Internal medicine, Medicine, Secretion, business, Lung cancer, medicine.disease, Hormone, Antidiuretic
Published
2021

26. PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results

Author

Monika Serke, Gunther H. Wiest, H. Sotoparra, E. Stoelben, Antonio Santo, G. Valmadre, I. Colantonio, F. Arizio, Alessandra Bearz, Christian Manegold, Alessandro Morabito, Frank Griesinger, G.V. Scagliotti, A. Ferrari, W. Schütte, Luca Porcu, Luisella Righi, Vanesa Gregorc, Michael Geissler, Martin Reck, Silvia Novello, Nicolas Dickgreber, M. Schena, Orazio Caffo, Valentina Monica, Mario Spatafora, F.L. Cecere, Christian Grohé, Valter Torri, G. Borra, Christian Schumann, Alessandro Follador, Rita Chiari, Luciana Irtelli, and A. Meyer

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Internal medicine, medicine, business, Adjuvant
Published
2021

28. Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer

Author

Di Maio, Massimo, Leighl, Natasha B., Gallo, Ciro, Feld, Ronald, Ciardiello, Fortunato, Butts, Charles, Maione, Paolo, Gebbia, Vittorio, Morgillo, Floriana, Wierzbicki, Rafal, Favaretto, Adolfo, Alam, Yasmin, Cinieri, Saverio, Siena, Salvatore, Bianco, Roberto, Riccardi, Ferdinando, Spatafora, Mario, Ravaioli, Alberto, Felletti, Raffaella, Fregoni, Vittorio, Genestreti, Giovenzio, Rossi, Antonio, Mancuso, Gianfranco, Fasano, Morena, Morabito, Alessandro, Tsao, Ming Sound, Signoriello, Simona, Perrone, Francesco, and Gridelli, Cesare

Published
2012
Full Text
View/download PDF

30. Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step Trial

Author

Gridelli, Cesare, Gallo, Ciro, Morabito, Alessandro, Iaffaioli, Rosario Vincenzo, Favaretto, Adolfo, Isa, Luciano, Barbera, Santi, Gamucci, Teresa, Ceribelli, Anna, Filipazzi, Virginio, Maione, Paolo, Rossi, Antonio, Barletta, Emiddio, Signoriello, Simona, De Maio, Ermelinda, Piccirillo, Maria Carmela, Di Maio, Massimo, Rocco, Gaetano, Vecchione, Aldo, and Perrone, Francesco

Published
2012
Full Text
View/download PDF

31. OA03.09 Overall Survival in Patients with EGFRM+ NSCLC Receiving Sequential Afatinib and Osimertinib: an Update of the Giotag Study

Author

D. Hao, C. Weinlinger, Angela Märten, Tanja Cufer, J.C.-H. Yang, Balazs Halmos, Alessandro Morabito, C.-T. Yang, Ross A. Soo, Rasim Gucalp, Maximilian Hochmair, and L. Wang

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Afatinib, Internal medicine, Overall survival, Medicine, Osimertinib, In patient, business, medicine.drug
Published
2019

32. P2.04-84 NSCLC Survival Expectancy for Patients Treated with Docetaxel/Nintedanib in the SENECA Trial and Previous Immunotherapy

Author

Angelo Delmonte, G. Osman, Salvatore Pisconti, Ludovica Ciuffreda, A. Misino, Anna Manzo, Ilaria Stura, Vieri Scotti, Rita Chiari, F. Di Costanzo, Rossana Critelli, Silvia Novello, Giuseppe Migliaretti, Emilio Bria, Enrica Capelletto, A.M. Morelli, Giulio Metro, I. Colantonio, Sara Ricciardi, Marcello Tiseo, A. Del Conte, Francesco Grossi, Alessandro Morabito, Vanesa Gregorc, G. Romano, and Maria Bonomi

Subjects
Pulmonary and Respiratory Medicine, Expectancy theory, Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Immunotherapy, chemistry.chemical_compound, chemistry, Docetaxel, Internal medicine, medicine, Nintedanib, business, medicine.drug
Published
2019

35. P2.02 Second-line Afatinib vs Erlotinib for Advanced Lung Squamous Cell Carcinoma: Final Analysis of the Phase 3 LUX-Lung 8 Trial

Author

Goss, G.D., primary, Cobo, M., additional, Lu, S., additional, Syrigos, K., additional, Lee, K.H., additional, Göker, E., additional, Georgoulias, V., additional, Li, W., additional, Isla, D., additional, Morabito, A., additional, Min, Y.J., additional, Ardizzoni, A., additional, Jian, H., additional, Yu, Y., additional, Bender, S., additional, Cseh, A., additional, and Felip, E., additional

Published
2019
Full Text
View/download PDF

37. P2.04-84 NSCLC Survival Expectancy for Patients Treated with Docetaxel/Nintedanib in the SENECA Trial and Previous Immunotherapy

Author

Capelletto, E., primary, Osman, G., additional, Morabito, A., additional, Chiari, R., additional, Grossi, F., additional, Tiseo, M., additional, Di Costanzo, F., additional, Delmonte, A., additional, Romano, G., additional, Misino, A., additional, Scotti, V., additional, Gregorc, V., additional, Pisconti, S., additional, Bonomi, M., additional, Del Conte, A., additional, Ciuffreda, L., additional, Colantonio, I., additional, Bria, E., additional, Ricciardi, S., additional, Manzo, A., additional, Metro, G., additional, Morelli, A., additional, Critelli, R., additional, Stura, I., additional, Migliaretti, G., additional, and Novello, S., additional

Published
2019
Full Text
View/download PDF

39. PL02.03 Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L)

Author

Scott N. Gettinger, J. Haney, M.R. Garcia Campelo, J-S. Lee, R. Camidge, K.H. Lee, Hwa Ryeon Kim, Cesare Gridelli, G-C. Chang, Alexander I. Spira, M-J. Ahn, M. Tiseo, Enriqueta Felip, Maximilian Hochmair, Raffaele Califano, S. Ghosh, Alessandra Bearz, J.Y. Li, Frank Griesinger, Dong Wook Kim, J.C.-H. Yang, David Kerstein, Alessandro Morabito, Sanjay Popat, J-Y. Han, and Angelo Delmonte

Subjects
Pulmonary and Respiratory Medicine, ALK inhibitor, Oncology, Brigatinib, Crizotinib, business.industry, medicine.drug_class, Cancer research, medicine, In patient, business, medicine.drug
Published
2018

40. P1.01-73 Preliminary Results of the SENECA (SEcond Line NintEdanib in Non-Small Cell Lung CAncer) Trial: An Italian Experience

Author

Giuseppe Migliaretti, F. Di Costanzo, Ilaria Stura, Emilio Bria, Enrica Capelletto, Vanesa Gregorc, G. Romano, Ludovica Ciuffreda, Rossana Critelli, Francesco Grossi, A. Del Conte, Vieri Scotti, Anna Manzo, Alessandro Morabito, A.M. Morelli, Giulio Metro, Rita Chiari, Maria Rita Migliorino, Marcello Tiseo, Sara Ricciardi, A. Misino, Angelo Delmonte, Salvatore Pisconti, Giovanni Luca Ceresoli, Silvia Novello, and I. Colantonio

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, medicine.disease, chemistry.chemical_compound, Second line, chemistry, Internal medicine, medicine, Nintedanib, Non small cell, Lung cancer, business
Published
2018

41. 57P Targeted sequencing of plasma-derived cfDNA in patients with metastatic NSCLC

Author

Alberto Morabito, Cristin Roma, A. De Luca, Nicola Normanno, Raffaella Pasquale, Francesca Bergantino, Laura Forgione, Francesca Fenizia, and Gaetano Rocco

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Plasma derived, Internal medicine, medicine, In patient, business
Published
2018

43. P2.02 Second-line Afatinib vs Erlotinib for Advanced Lung Squamous Cell Carcinoma: Final Analysis of the Phase 3 LUX-Lung 8 Trial

Author

Shaun Bender, M. Cobo, Dolores Isla, Agnieszka Cseh, Yongfeng Yu, K.H. Lee, Kostas N. Syrigos, Vassilis Georgoulias, Enriqueta Felip, Wei Li, Glenwood D. Goss, Alessandro Morabito, Andrea Ardizzoni, Shaoyong Lu, Erdem Göker, Hong Jian, and Young Joo Min

Subjects
Pulmonary and Respiratory Medicine, Second line, Lung, medicine.anatomical_structure, Oncology, business.industry, Afatinib, Lung squamous cell carcinoma, medicine, Cancer research, Erlotinib, business, medicine.drug
Published
2019

44. P1.01-118 Overall Survival in Pts with EGFRm+ NSCLC Receiving Sequential Afatinib and Osimertinib: Updated Analysis of the GioTag Study

Author

Angela Märten, D. Hao, Tanja Cufer, C.-T. Yang, L. Wang, Rasim Gucalp, Ross A. Soo, Maximilian Hochmair, J.C.-H. Yang, Alessandro Morabito, and Balazs Halmos

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Afatinib, Internal medicine, medicine, Overall survival, Osimertinib, business, medicine.drug
Published
2019

45. OA03 Afatinib Followed by Osimertinib in Real-World Patients with EGFR Mutation-Positive Advanced NSCLC: The Giotag Study

Author

Balazs Halmos, D. Hao, Angela Märten, Tanja Cufer, C.-T. Yang, Amanda K. Golembesky, Maximilian Hochmair, J.C.-H. Yang, Ross A. Soo, Rasim Gucalp, and Alessandro Morabito

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Egfr mutation, Afatinib, Internal medicine, medicine, Osimertinib, business, medicine.drug
Published
2018

46. PL02.03 Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L)

Author

Camidge, R., primary, Kim, H.R., additional, Ahn, M., additional, Yang, J.C., additional, Han, J., additional, Lee, J., additional, Hochmair, M., additional, Li, J.Y., additional, Chang, G., additional, Lee, K., additional, Gridelli, C., additional, Delmonte, A., additional, Garcia Campelo, M.R., additional, Kim, D., additional, Bearz, A., additional, Griesinger, F., additional, Morabito, A., additional, Felip, E., additional, Califano, R., additional, Ghosh, S., additional, Spira, A., additional, Gettinger, S., additional, Tiseo, M., additional, Haney, J., additional, Kerstein, D., additional, and Popat, S., additional

Published
2018
Full Text
View/download PDF

47. P1.01-73 Preliminary Results of the SENECA (SEcond Line NintEdanib in Non-Small Cell Lung CAncer) Trial: An Italian Experience

Author

Capelletto, E., primary, Migliorino, M.R., additional, Morabito, A., additional, Chiari, R., additional, Grossi, F., additional, Tiseo, M., additional, Di Costanzo, F., additional, Delmonte, A., additional, Romano, G., additional, Misino, A., additional, Scotti, V., additional, Gregorc, V., additional, Pisconti, S., additional, Ceresoli, G., additional, Del Conte, A., additional, Ciuffreda, L., additional, Colantonio, I., additional, Bria, E., additional, Ricciardi, S., additional, Manzo, A., additional, Metro, G., additional, Morelli, A.M., additional, Critelli, R., additional, Stura, I., additional, Migliaretti, G., additional, and Novello, S., additional

Published
2018
Full Text
View/download PDF

48. P13 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung

Author

Goss, G., primary, Cobo, M., additional, Lu, S., additional, Syrigos, K., additional, Lee, K.H., additional, Göker, E., additional, Georgoulias, V., additional, Li, W., additional, Isla, D., additional, Young, J.M., additional, Morabito, A., additional, Gadgeel, S., additional, Gibson, N., additional, Krämer, N., additional, Solca, F., additional, Cseh, A., additional, and Felip, E., additional

Published
2018
Full Text
View/download PDF

50. P3.01-043 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung

Author

Wei Li, Alessandro Morabito, M. Cobo, Dolores Isla, Flavio Solca, Nicole C. Krämer, K.H. Lee, Andrea Ardizzoni, Salih Zeki Guclu, E. Ehrnrooth, Shun Lu, Enriqueta Felip, Kostas N. Syrigos, J-C. Soria, Shirish M. Gadgeel, Vassilis Georgoulias, Neil W. Gibson, Agnieszka Cseh, Erdem Göker, Y. Joo Min, and Glenwood D. Goss

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung, business.industry, Afatinib, 03 medical and health sciences, 0302 clinical medicine, medicine.anatomical_structure, ErbB, 030220 oncology & carcinogenesis, Internal medicine, Medicine, 030212 general & internal medicine, Erlotinib, business, medicine.drug
Published
2017

Catalog

Books, media, physical & digital resources
See catalog results